AEZS

Aeterna Zentaris Inc. [AEZS] Stock Forecast

Q: What is Aeterna Zentaris Inc. stock symbol ?

Aeterna Zentaris Inc. is a US stock, located in Summerville of Sc and trading under the symbol AEZS

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

AEZS Stock Summary

Earnings have grown 44.03% per last year.

Earnings are expected to rise 723.4% next year

EPS has been increasing for the past 3 years (Yearly statements)

Currently unprofitable, and not expected to turn profitable in the coming year

Does not have any significance market cap ($13.18M)

AEZS has less than 1 year of cash runway

Top AEZS Correlated Resources

AEZS

Top 10 Correlated ETFs

AEZS

Top 10 Correlated Stocks

AEZS

In the News

11:19 22 Mar 2023 AEZS

Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?

Here is how Aeterna Zentaris (AEZS) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.

08:05 22 Mar 2023 AEZS

Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event

Live video webcast on Thursday , January 19 th at 3 :00 PM ET

08:00 22 Mar 2023 AEZS

Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference

TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.

08:05 22 Mar 2023 AEZS

Aeterna Zentaris to Present at the 2022 BIO CEO & Investor Conference

CHARLESTON, S.C., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini , Chief Executive Officer of Aeterna Zentaris, will present at the BIO CEO & Investor Conference being held in New York, NY and virtually, February 14-17, 2022.

08:05 22 Mar 2023 AEZS

Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference

– Live video webcast presentation on Wednesday, January 26 th at 9:00 AM ET

08:36 22 Mar 2023 AEZS

Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference

CHARLESTON, S.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini , Chief Executive Officer of Aeterna Zentaris, will present at the virtual H.C. Wainwright Bio C onnect Conference taking place January 10-13, 2022.

12:46 22 Mar 2023 AEZS

3 Hot Penny Stocks: Why ZOM, AEZS and PROG Are Seeing Big Gains Today

A few hot penny stocks are seeing major movement on Friday as shares ride higher and we've got all the details traders need. The post 3 Hot Penny Stocks: Why ZOM, AEZS and PROG Are Seeing Big Gains Today appeared first on InvestorPlace.

08:00 22 Mar 2023 AEZS

Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

CHARLESTON, S.C., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini , Chief Executive Officer of Aeterna, will present at the virtual H.C. Wainwright 23 rd Annual Global Investment Conference taking place September 13-15, 2021.

08:05 22 Mar 2023 AEZS

Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing

CHARLESTON, S.C., July 29, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that on July 28, 2021, the Company received notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, based upon a closing bid price of less than $1.00 per share for the Company's common stock for the prior 30 consecutive business day period, the Company no longer satisfies Nasdaq Listing Rule 5550(a)(2) (the “Rule”).

01:09 22 Mar 2023 AEZS

Best Penny Stocks To Buy Now? 7 To Watch This Week

What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?

AEZS Financial details

Company Rating

Neutral

Market Cap

13.18M

Income

-10.94M

Revenue

7.45M

Book val./share

10.18

Cash/share

11.08

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

27 Mar 2023

P/E

-1.4

Forward P/E

PEG

0.47

P/S

1.89

P/B

0.26

P/C

0.24

P/FCF

-1.62

Quick Ratio

9.37

Current Ratio

9.82

Debt / Equity

0.35

LT Debt / Equity

EPS (TTM)

-2.11

EPS next Y

EPS next Q

-0.47

EPS this Y

-41.67%

EPS next Y

EPS next 5Y

-38978.5%

EPS last 5Y

-42.57%

Revenue last 5Y

41.63%

Revenue Q/Q

22.61%

EPS Q/Q

40%

SMA20

SMA50

SMA100

-25%

Inst Own

0.72%

Inst Trans

-14.04%

ROA

-14%

ROE

-18%

ROC

-0.16%

Gross Margin

98%

Oper. Margin

-145%

Profit Margin

-135%

Payout

Shs Outstand

4.86M

Shs Float

4.85M

Target Price

52W Range

2.54-9.75

52W High

-70.44%

52W Low

+33%

RSI

Rel Volume

Avg Volume

14.91K

Volume

44.73K

Perf Week

1.92%

Perf Month

-29.07%

Perf Quarter

-32.14%

Perf Half Y

-41.54%

Beta

1.72548

Volatility

0.04%, 0.36%

Prev Close

Price

2.66

Change

2.31%

AEZS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31
Revenue per share	1.54	40.88	0.76	2.22	1.14
Net income per share	-28.07	6.37	-8.63	-3.11	-1.82
Operating cash flow per share	-38.29	10.38	-15.33	-2.51	-1.87
Free cash flow per share	-38.3	10.36	-15.33	-2.51	-2.01
Cash per share	13	22.07	11.2	14.77	14.2
Book value per share	-4.65	2.9	-3.52	8.04	11.53
Tangible book value per share	-19.2	-9.68	-15.08	2.64	9.62
Share holders equity per share	-4.65	2.9	-3.52	8.04	11.53
Interest debt per share	0.13	0.42	2.14	-0.34	0.04
Market cap	35.3M	48.34M	15.92M	17.48M	40.83M
Enterprise value	27.52M	33.82M	8.98M	-6.61M	-24.31M
P/E ratio	-2.1	11.54	-2.63	-3.42	-4.88
Price to sales ratio	38.25	1.8	29.92	4.79	7.76
POCF ratio	-1.54	7.08	-1.48	-4.23	-4.76
PFCF ratio	-1.54	7.09	-1.48	-4.23	-4.43
P/B Ratio	-12.69	25.35	-6.46	1.32	0.77
PTB ratio	-12.69	25.35	-6.46	1.32	0.77
EV to sales	29.82	1.26	16.89	-1.81	-4.62
Enterprise value over EBITDA	-1.37	3.39	-1.69	1.26	2.92
EV to operating cash flow	-1.2	4.96	-0.84	1.6	2.83
EV to free cash flow	-1.2	4.96	-0.84	1.6	2.64
Earnings yield	-0.48	0.09	-0.38	-0.29	-0.2
Free cash flow yield	-0.65	0.14	-0.67	-0.24	-0.23
Debt to equity	-8.98	12.12	-9.11	1.82	0.51
Debt to assets	1.13	0.92	1.12	0.65	0.34
Net debt to EBITDA	0.39	-1.45	1.3	4.61	7.84
Current ratio	1.63	2.9	1.93	5.56	9.12
Interest coverage	-307.65	35.4	-17.27	7.75	-412.9
Income quality	1.36	1.63	1.78	0.81	1.03
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	8.88	0.33	12.43	1.3	1.12
Research and developement to revenue	11.6	0.11	3.45	0.41	1.25
Intangibles to total assets	0.39	0.33	0.4	0.24	0.11
Capex to operating cash flow	0	0	0	0	0.07
Capex to revenue	0	0	0	0	-0.12
Capex to depreciation	-0.04	-0.16	0	0	-4.41
Stock based compensation to revenue	0.2	0.02	1.49	0.02	0.06
Graham number	54.2	20.38	26.15	23.73	21.73
ROIC	-3.53	-0.81	-3.09	0.5	0.17
Return on tangible assets	-1.24	0.25	-0.51	-0.18	-0.12
Graham Net	-27.93	-12.55	-19.31	0.9	8.91
Working capital	3.61M	10.66M	5.25M	22.87M	63.05M
Tangible asset value	-11.49M	-6.37M	-10.55M	4.34M	44.23M
Net current asset value	-15.6M	-6.85M	-11.53M	3.82M	43.7M
Invested capital	0	0	-0.37	0.01	0
Average receivables	293K	257.5K	476K	1.17M	2.68M
Average payables	1.63M	1.25M	1.18M	1.14M	1.06M
Average inventory	321.5K	441.5K	721.5K	612K	47K
Days sales outstanding	87.39	3.99	451.45	168.01	255.01
Days payables outstanding	0	222.4	967.7	186.99	3.79K
Days of inventory on hand	0	41.63	1.07K	3.31	296.06
Receivables turnover	4.18	91.43	0.81	2.17	1.43
Payables turnover	0	1.64	0.38	1.95	0.1
Inventory turnover	0	8.77	0.34	110.33	1.23
ROE	6.04	2.2	2.45	-0.39	-0.16
Capex per share	-0.01	-0.01	0	0	-0.14

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric	2021-06-30	2021-09-30	2021-12-31	2022-03-31	2022-09-30
Revenue per share	0.12	0.12	0.72	0.31	0.38
Net income per share	-0.42	-0.35	-0.66	-0.54	-0.7
Operating cash flow per share	-0.75	-0.31	-0.5	-0.3	-0.81
Free cash flow per share	-0.75	-0.31	-0.52	-0.3	-0.81
Cash per share	14.41	14.02	13.46	13.1	11.08
Book value per share	12.65	12.35	10.92	10.95	10.18
Tangible book value per share	10.78	10.5	9.12	9.18	8.62
Share holders equity per share	12.65	12.35	10.92	10.95	10.18
Interest debt per share	0.03	0.04	0.03	0.03	0.02
Market cap	106.28M	90.97M	43.1M	44.63M	18.62M
Enterprise value	36.53M	23.17M	-22.04M	-18.81M	-35.11M
P/E ratio	-13.03	-13.39	-3.38	-4.23	-1.36
Price to sales ratio	177.43	151.12	12.41	29.42	10.01
POCF ratio	-29.24	-61.14	-17.86	-30.54	-4.72
PFCF ratio	-29.21	-60.93	-16.99	-30.42	-4.71
P/B Ratio	1.73	1.52	0.81	0.84	0.38
PTB ratio	1.73	1.52	0.81	0.84	0.38
EV to sales	60.99	38.49	-6.35	-12.4	-18.87
Enterprise value over EBITDA	-18.3	-13.95	7.05	7.22	10.37
EV to operating cash flow	-10.05	-15.57	9.13	12.87	8.9
EV to free cash flow	-10.04	-15.52	8.69	12.82	8.88
Earnings yield	-0.02	-0.02	-0.07	-0.06	-0.18
Free cash flow yield	-0.03	-0.02	-0.06	-0.03	-0.21
Debt to equity	0.37	0.37	0.51	0.44	0.35
Debt to assets	0.27	0.27	0.34	0.3	0.26
Net debt to EBITDA	34.94	40.82	20.84	24.35	15.86
Current ratio	16.43	15.16	9.12	11.84	9.82
Interest coverage	-302	-454.5	0	2.81K	0
Income quality	1.78	0.88	0.76	0.55	1.15
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	2.75	2.04	0.51	1.03	1.11
Research and developement to revenue	1.23	1.33	1.35	1.58	1.77
Intangibles to total assets	0.11	0.11	0.11	0.11	0.11
Capex to operating cash flow	0	0	0.05	0	0
Capex to revenue	-0.01	-0.01	-0.04	0	0
Capex to depreciation	-0.08	-0.15	-3.1	-0.17	-0.27
Stock based compensation to revenue	0.43	0.03	0.01	0.02	0.24
Graham number	10.94	9.86	12.7	11.57	12.7
ROIC	0.04	0.03	0.07	0.05	0.09
Return on tangible assets	-0.03	-0.02	-0.04	-0.04	-0.06
Graham Net	9.9	9.6	8.45	8.69	7.89
Working capital	70.18M	67.62M	63.05M	61.43M	52.64M
Tangible asset value	52.27M	50.96M	44.23M	44.57M	41.85M
Net current asset value	51.72M	50.28M	43.7M	43.91M	41.42M
Invested capital	0	0	0	0	0
Average receivables	1.28M	1.2M	2.29M	2.92M	0
Average payables	826.5K	639.5K	803K	978K	0
Average inventory	59.5K	58K	65K	175.5K	0
Days sales outstanding	224.32	136.05	95.23	128.92	100.74
Days payables outstanding	4.55K	1.95K	4.67K	1.16K	4.63K
Days of inventory on hand	442.5	165.48	365	316.71	1.53K
Receivables turnover	0.4	0.66	0.95	0.7	0.89
Payables turnover	0.02	0.05	0.02	0.08	0.02
Inventory turnover	0.2	0.54	0.25	0.28	0.06
ROE	-0.03	-0.03	-0.06	-0.05	-0.07
Capex per share	0	0	-0.03	0	0

AEZS Frequently Asked Questions

What is Aeterna Zentaris Inc. stock symbol ?

Aeterna Zentaris Inc. is a US stock , located in Summerville of Sc and trading under the symbol AEZS

What is Aeterna Zentaris Inc. stock quote today ?

Aeterna Zentaris Inc. stock price is $2.66 today.

Is Aeterna Zentaris Inc. stock public?

Yes, Aeterna Zentaris Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 14.91K
Market Capitalization 13.18M
Employee 12
CEO Dr. Klaus Paulini Ph.D.
Headquarters Summerville,SC,US
IPO Date 1995-12-19
Website https://www.zentaris.com

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.